Skip to main content

Table 1 Clinical and virological characteristics of patients with a history of HCC treatments before and after DAA therapy

From: AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy

Age (years)

71.7 ± 8.0

Sex (male/female)

126/73

Body mass index (kg/m2)

23.2 ± 3.2

White blood cell count (/μL)

4295 ± 1370

Platelet count (× 104/μL)

11.9 ± 8.0

ALT (U/L)

47.1 ± 30.3

AST (U/L)

52.3 ± 26.7

Total bilirubin (mg/dL)

0.8 ± 0.4

Albumin (g/dL)

3.8 ± 0.4

Prothrombin time (%)

82.9 ± 15.4

AFP (ng/mL)

20.8 ± 53.0

eGFR (mL/min/1.73 m2)

67.7 ± 20.3

Total cholesterol (mg/dL)

151.5 ± 27.9

Diabetes mellitus (no/yes)

149/49

Alcohol (none/drinking/unknown)

152/22/25

FIB-4 index

5.8 ± 3.7

APRI

1.6 ± 1.5

HCV RNA (log copies/mL)

5.8 ± 0.7

Post-treatment ALT (U/L)

22.8 ± 22.4

Post-treatment AST (U/L)

29.4 ± 16.4

Post-treatment total bilirubin (mg/dL)

0.8 ± 0.4

Post-treatment albumin (g/dL)

3.9 ± 0.4

Post-treatment prothrombin time (%)

83.5 ± 15.8

Post-treatment AFP (ng/mL)

8.2 ± 10.5

Post-treatment eGFR (mL/min/1.73 m2)

65.6 ± 19.3

SVR/no SVR

184/15

Child-Pugh class (A/B/C/unknown)

161/26/1/11

BCLC stage (0/A/B/C/D)

81/49/31/35/3

Latest HCC treatment (RFA/surgical resection)

178/21

Number of months from HCC treatment to DAA therapy initiation

20 ± 26

Number of curative treatments for HCC

1.1 ± 1.5

DAA therapy (SOF + LDV/SOF + RBV/ASV + DCV/OBV + PTV + r/EBR + GZR)

90/26/53/18/12

  1. Data are expressed as means ± standard deviation
  2. ALT alanine aminotransferase; AST aspartate aminotransferase; AFP α-fetoprotein; eGFR estimated glomerular filtration rate; FIB-4 fibrosis-4; APRI AST to platelet ratio index; HCV hepatitis C virus; RNA ribonucleic acid; SVR sustained virological response; BCLC Barcelona Clinic Liver Cancer; RFA radiofrequency ablation; DAA direct-acting antiviral; SOF sofosbuvir; LDV ledipasvir; RBV ribavirin; ASV asunaprevir; DCV daclatasvir; OBV ombitasvir; PTV paritaprevir; r ritonavir; EBR elbasvir; GZR grazoprevir